Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia
- PMID: 21796762
- PMCID: PMC3495615
- DOI: 10.1002/pbc.23249
Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia
Comment on
-
A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.Pediatr Blood Cancer. 2011 Aug;57(2):231-9. doi: 10.1002/pbc.22936. Epub 2011 Feb 22. Pediatr Blood Cancer. 2011. PMID: 21344614
References
-
- Donnan JR, Ungar WJ, Mathews M, et al. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer - PubMed
-
- van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7(5):783–792. - PubMed
-
- Schutz E, Gummert J, Mohr F, et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341(8842):436. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical